On October 6, 2026, the clinical trial registry listed an update for a study of anamorelin hydrochloride. The trial, titled "Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer," is registered under identifier NCT03637816. It is listed as Phase 2/Phase 3. The current status is active, not recruiting, meaning the study is ongoing but is no longer enrolling new participants. Anamorelin remains classified as an unapproved compound under research investigation. No results or outcome data have been reported as part of this status update. The trial record does not indicate findings related to efficacy or safety at this time. This update reflects only the enrollment and operational status of the study as registered. Patients, caregivers, and researchers interested in the trial's design or eligibility criteria can review the full registry entry for further detail. For additional background on anamorelin, including its research classification and general information, readers can consult the compound overview.
Anamorelin Trial for NSCLC Anorexia Now Active, Not Recruiting
See the full anamorelin overview
Source: https://clinicaltrials.gov/study/NCT03637816